Authors:
CM Connell, SEM Raby, I Beh, TR Flint, EH Williams, DT Fearon, DI Jodrell, T Janowitz
Journal name: 
Oncologist
Citation info: 
23(1):116-117
Abstract: 
Immune-related radiological and biomarker monitoring in cancer immunotherapy trials permits interrogation of efficacy and reasons for therapeutic failure. We report the results from a cross-sectional analysis of response monitoring in 685 T-cell checkpoint-targeted cancer immunotherapy trials in solid malignancies, as registered on the U.S. National Institutes of Health trial registry by October 2016. Immune-related radiological response criteria were registered for only 25% of clinical trials. Only 38% of trials registered an exploratory immunological biomarker, and registration of immunological biomarkers has decreased over the last 15 years. We suggest that increasing the utilization of immune-related response monitoring across cancer immunotherapy trials will improve analysis of outcomes and facilitate translational efforts to extend the benefit of immunotherapy to a greater proportion of patients with cancer.
DOI: 
http://doi.org/10.1634/theoncologist.2017-0226
Research group: 
Jodrell Group
E-pub date: 
31 Jan 2018